Motif Bio plc: Motif Bio Presents New Iclaprim Data at ASM Microbe 2019

MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer

CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution

Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology

Medigene AG: Interim analysis from ongoing Phase I/II clinical trial with DC vaccines in AML patients presented at EHA

InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

Probiodrug AG becomes Vivoryon Therapeutics AG

Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD